Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Sushma Kumar"'
Autor:
Brian M. Maas, Julie Strizki, Randy R. Miller, Sushma Kumar, Michelle Brown, Matthew G. Johnson, Mickie Cheng, Carisa De Anda, Matthew L. Rizk, Julie A. Stone
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP ser
Externí odkaz:
https://doaj.org/article/80235adabbc14c2b94f7c558ebb6cf63
Autor:
Sharma, Anjali, Das, Karobi, Saini, Sushma Kumar, Ghai, Sandhya, Mittal, Sandeep, Kaur, Manmeet
Publikováno v:
Indian Journal of Community Medicine, Vol 46, Iss 2, Pp 221-225 (2021)
Indian Journal of Community Medicine : Official Publication of Indian Association of Preventive & Social Medicine
Indian Journal of Community Medicine : Official Publication of Indian Association of Preventive & Social Medicine
Purpose: Men who have sex with men (MSM) is a vulnerable group, who have been neglected and discriminated. Such discrimination decreases their access to health care and increases the spread of sexually transmitted infections (STIs) and human immunode
Autor:
George J. Hanna, Hedy Teppler, Elizabeth Martin, Gina Lin, Sushma Kumar, Chloe Orkin, Otto Sussmann, Jean-Michel Molina, Kathleen Squires, Paul E. Sax, Carey Hwang
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Doravirine (DOR) is a nonnucleoside reverse-transcriptase inhibitor. In the phase 3 DRIVE-AHEAD trial in treatment-naive adults with human immunodeficiency virus type 1 (HIV-1) infection, DOR demonstrated noninferior efficacy compared with
Autor:
Donald J. Graham, Elizabeth Martin, Ming-Tain Lai, Peter Sklar, Meizhen Feng, Winnie Ngo, Carey Hwang, Sushma Kumar, Daria J. Hazuda, Ernest Asante-Appiah
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Background Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV-1 infection in patients with no known DOR resistance-associated mutations. DOR was rationally designed to address limitati
Autor:
Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Edwin DeJesus, Ming-Tain Lai, Anthony Rodgers, Lisa Lupinacci, Sushma Kumar, Peter Sklar, George J Hanna, Carey Hwang, Elizabeth Anne Martin, Debbie P. Hagins, Olayemi O. Osiyemi, David James Prelutsky, Moti N. Ramgopal, Anthony John Scarsella, Robin Dretler, Christopher J. Bettacchi, James Sims, Patrick G. Clay, Nicholaos C. Bellos, Melanie A. Thompson, Jose Montero, Cheryl K. McDonald, Catherine Creticos, David Shamblaw, Miguel Mogyoros, Antonio E. Terrelonge, Martin Valdes, Karen T. Tashima, William J. Robbins, Franco Antonio Felizarta, Richard A. Elion, Jihad Slim, Sandra S. Win, Sujata N. Lalla-Reddy, Peter Jerome Ruane, Anthony Mills, Jerry L. Cade, Craig A. Dietz, David Scott Rubin, Cynthia Mayer, Juan Carlos Rondon, Paul P. Cook, Eric Daar, Princy N. Kumar, Susan Swindells, Jose Guillermo Castro, Ivan Melendez-Rivera, Javier O. Morales-Ramirez, Lizette Santiago, Jorge L. Santana-Bagur, Marcelo Martins, Pedro Enrique Cahn, Gustavo D. Lopardo, Norma Porteiro, Mark Theo Bloch, David Alfred Baker, Norman Roth, Richard James Moore, Robert James Finlayson, James McMahon, Armin Rieger, Alexander Zoufaly, Sylvia Hartl, Robert Zangerle, Fiona Smaill, Sharon L. Walmsley, Brian Conway, Anita Rachlis, Graham H.R. Smith, Carlos Perez, Alejandro Afani, Maria Isabel Campos, Carolina Eugenia Chahin, Marcelo Wolff Reyes, Jan Gerstoft, Nina Weis, Alex Lund Laursen, Yazdan Yazdanpanah, Laurent Cotte, Francois Raffi, Philippe Morlat, Pierre-Marie Girard, Christine Katlama, Juergen K. Rockstroh, Keikawus Arasteh, Stefan Esser, Albrecht Stoehr, Hans-Juergen Stellbrink, Matthias Stoll, Dirk Schuermann, Gerd Faetkenheuer, Johannes Bogner, Thomas Lutz, Axel Baumgarten, Hans Jaeger, Andrea Gori, Gabriel Coltan, Felicia Constandis, Simona Manuela Erscoiu, Liviu-Jany Prisacariu, Sorin Rugina, Adrian Streinu-Cercel, Vadim Valentinovich Pokrovsky, Natalia V. Zakharova, Andrey Anatolyevich Shuldyakov, Elena Pavlovna Ryamova, Valeriy Viktorovich Kulagin, Olga Aleksandrovna Tsybakova, Elena Orlova-Morozova, Firaya Nagimova, Evgeniy Voronin, Tatyana Evgenyevna Shimonova, Oleg Anatolyevich Kozyrev, Catherine Orrell, Johannes Jurgens Lombaard, Marleen de Jager, Joaquin Portilla Segorb, Josep Mallolas, Maria Jesus Perez Elias, Josep M. Gatell, Jose Ramon Arribas Lopez, Eugenia Negredo Puigmal, Daniel Podzamczer Palter, Federico Pulido Ortega, Jesus Troya Garcia, Ignacio De los Santos Gil, Juan Berenguer Berenguer, Ian G. Williams, Margaret A. Johnson, Gabriel Schembri, Amanda Clarke, Mark Gompels, Julie Meriel Fox, Steven John Taylor, David Harold Dockrell, Stephen Kegg
Publikováno v:
The Lancet HIV. 7:e16-e26
Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults with HIV who were treatment naive at week 48 in the phase 3 DRIVE-FORW
Autor:
Pedro Cahn, Jean-michel Molina, Johan Lombaard, Kathleen Squires, Sushma Kumar, Hong Wan, Valerie Teal, Ernest Asante-Appiah, Peter Sklar, Elizabeth A Martin, Rima Lahoulou
Publikováno v:
Open Forum Infectious Diseases
Background DRIVE-FORWARD is a phase 3 trial with a completed double-blind period comparing doravirine (DOR) 100 mg with ritonavir-boosted darunavir (DRV/r) 800/100 mg, both administered with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs;
Autor:
George J. Hanna, Sushma Kumar, Anthony Rodgers, Elizabeth Martin, Jean-Michel Molina, Chloe Orkin, Edwin DeJesus, Carey Hwang, Johan Lombaard
Publikováno v:
Clinical Infectious Diseases. 70:1344-1352
BackgroundDoravirine (DOR) demonstrated noninferior efficacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2 ongoing phase 3 trials: DRIVE-FORWARD (NCT02275780) and DRIVE-AHEAD (NCT02403674).MethodsThis prespecified analysis pooled effic
Autor:
Alexander Wong, Deborah Goldstein, Anthony Rodgers, Sushma Kumar, Peter Sklar, Valerie L Teal, Cyrus Badshah, Hedy Teppler, George J. Hanna, Anton Pozniak, Josep Mallolas, Deborah A. Hepler, Edwin DeJesus, Carey Hwang, Jean-Michel Molina, Margaret A. Johnson
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Autor:
Jean-Michel Molina, Sushma Kumar, Carey Hwang, George J. Hanna, Pedro Cahn, Kathleen Squires, Melanie Thompson, Hedy Teppler, Xia Xu, Chloe Orkin, Paul E. Sax, Anthony Rodgers, Elizabeth Martin
Publikováno v:
Clinical Infectious Diseases.
Background A prespecified integrated safety analysis was conducted for 3 doravirine (DOR) double-blind trials (Phase IIb: P007 [NCT01632345]; Phase III: DRIVE-FORWARD [NCT02275780] and DRIVE-AHEAD [NCT02403674]). Methods DOR (100 mg) arms from these
Autor:
Lisa Lupinacci, Jean-Michel Molina, George J. Hanna, Xia Xu, Bach-Yen Nguyen, Anthony Rodgers, Paul E. Sax, Otto Sussmann, Gina Lin, Kathleen Squires, Carey Hwang, Richard Kaplan, Wing-Wai Wong, Sushma Kumar, Elizabeth Martin, Peter Sklar, Chloe Orkin
Publikováno v:
Orkin, C, Squires, K E, Molina, J-M, Sax, P E, Wong, W-W, Sussmann, O, Kaplan, R, Rodgers, A, Nguyen, B-Y, Hwang, C, Hanna, G J, Lin, G, Lupinacci, L, Sklar, P, Kumar, S, Xu, X, Martin, E A, DRIVE-AHEAD Study Group & Nielsen, H I 2019, ' Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection : Week 48 Results of the DRIVE-AHEAD Trial ', Clinical Infectious Diseases, vol. 68, no. 4, pp. 535-544 . https://doi.org/10.1093/cid/ciy540
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In Human Immunodeficiency Virus–1 treatment-naive adults, a fixed combination of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferior antiretroviral efficacy to efavirenz/emtricitabine/tenofovir disoproxil fumarate at week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c028126be8e1266771d94634943aab21
https://vbn.aau.dk/ws/files/295149929/Orkin_et_al_2019_Doravirine_....pdf
https://vbn.aau.dk/ws/files/295149929/Orkin_et_al_2019_Doravirine_....pdf